Chemistry:Lexanopadol
From HandWiki
Lexanopadol (INN, USAN), also known by its developmental code name GRT-6006, is an opioid receptor modulator which was under development for the treatment of pain.[1][2][3] It is taken orally.[1] The drug acts as a dual agonist of the μ-opioid receptor and nociceptin receptor.[1][2][3] It is thought that the combination of these activities may confer enhanced analgesic efficacy.[3] Lexanopadol was under development by Grünenthal.[1][2] It reached phase 1 or 2 clinical trials prior to the discontinuation of its development, with no further development reported by 2016.[1][2] The drug was a follow-on compound to cebranopadol (GRT-6005).[3][4]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Lexanopadol". 20 August 2018. https://adisinsight.springer.com/drugs/800034083.
- ↑ 2.0 2.1 2.2 2.3 "Delving into the Latest Updates on Lexanopadol Hemicitrate with Synapse". 19 November 2025. https://synapse.patsnap.com/drug/bddae87017624de2b9b934625f525044.
- ↑ 3.0 3.1 3.2 3.3 "Buprenorphine in the Treatment of Neuropathic Pain". Research and Development of Opioid-Related Ligands. ACS Symposium Series. 1131. Washington, DC: American Chemical Society. 2013. pp. 103–123. doi:10.1021/bk-2013-1131.ch006. ISBN 978-0-8412-2782-8. "Recently, Grünenthal and Forest Laboratories have entered into a license agreement for the co-development of a novel oral small-molecule analgesic, GRT 6005, and its follow-on compound GRT 6006 (98–100). Both compounds were discovered and developed by Grünenthal and represent novel first in class molecules with unique pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 and 6006 are novel first in class compounds with potent agonist activity on ORL-1 (opioid receptor like -1) and the well established mu opioid receptor. Preliminary evidence (93, 100, 101) suggests that targeting ORL-1 receptors may have synergistic effects with mu receptors hence enhancing the therapeutic profile of the compounds in the treatment of pain."
- ↑ "Forest Laboratories and Gruenenthal Enter Into Licensing Agreement for the Development and Commercialization of Novel Anal". 6 December 2010. https://www.fiercebiotech.com/biotech/forest-laboratories-and-gruenenthal-enter-into-licensing-agreement-for-development-and.
 |  |
